Abpro Holdings, Inc. (ABP)
| Market Cap | 6.38M |
| Revenue (ttm) | n/a +50.0% |
| Net Income | -22.04M |
| EPS | -11.90 |
| Shares Out | 2.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 288,958 |
| Open | 2.080 |
| Previous Close | 2.024 |
| Day's Range | 2.061 - 2.900 |
| 52-Week Range | 2.001 - 39.600 |
| Beta | 0.01 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Apr 2, 2026 |
About ABP
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company’s lead product candid... [Read more]
Financial Performance
In 2024, Abpro Holdings's revenue was $183,000, an increase of 50.00% compared to the previous year's $122,000. Losses were -$17.41 million, 48.7% more than in 2023.
Financial StatementsNews
Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today...
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
FDA clearance enables initiation of Abpro's first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro's global collaboration with Celltrio...
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpr...
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announce...
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for CT-P72/...
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance...
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-thr...
Abpro Statement on the Departure of Former CEO Ian Chan
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-thr...
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing
WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening di...